Disitamab Vedotin vs Trastuzumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
No aligned efficacy figure on record for this race.
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03505710 · Phase 2 · terminated
Participants were placed in cohorts by HER2 status and dose without randomization, nobody was blinded to treatment, and there was no comparison arm. Response rates were read by an independent central reviewer but are reported for each cohort on its own.
Next expected readout: December 2026 · NCT06250777 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70) (not_applicable)
Result source: NCT04644237
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Disitamab Vedotin | Trastuzumab Deruxtecan |
|---|---|---|
| PFS, median | —Not reported | 9.5bNCT046442371 other result
|
| OS, median | —Not reported | 17.9bNCT046442371 other result
|
| ORR | —Not reported | 56%bNCT046442373 other results
|
| Duration of response, median | —Not reported | 12.9bNCT046442371 other result
|
PFS, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab Deruxtecan
- 9.5bNCT04644237
1 other result
- 9.7 NCT04644237
OS, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab Deruxtecan
- 17.9bNCT04644237
1 other result
- 19 NCT04644237
ORR
- Disitamab Vedotin
- —Not reported
- Trastuzumab Deruxtecan
- 56%bNCT04644237
3 other results
- 50% NCT04644237
- 56% NCT04644237
- 46.1% NCT04644237
Duration of response, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab Deruxtecan
- 12.9bNCT04644237
1 other result
- 11.1 NCT04644237
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Disitamab Vedotin: 0 of 4 rows · Trastuzumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Trastuzumab Deruxtecan |
|---|---|
| Dropout rate | n/a: no completion milestone6.4 mg/kga NCT04644237 · Phase 2 show 1 more resultn/a: no completion milestone5.4 mg/kg NCT04644237 · Phase 2 |
| Discontinued due to AEs | 38%6.4 mg/kga NCT04644237 · Phase 2 show 1 more result17.6%5.4 mg/kg NCT04644237 · Phase 2 |
| Serious AEs | 52%6.4 mg/kga NCT04644237 · Phase 2 show 1 more result41.6%5.4 mg/kg NCT04644237 · Phase 2 |
| Most frequent reported AEs | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trastuzumab Deruxtecan
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT03500380 · Phase 2/3 · status unknown
This trial randomized 301 patients with HER2-positive metastatic breast cancer to disitamab vedotin or an active comparator regimen (lapatinib plus capecitabine), with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT07366840 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by an IRC (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months): Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). (met)
Result source: NCT03500380
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03523585 · Phase 3 · completed
The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.
Next expected readout: January 2027 · NCT06797622 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) (met)
Result source: NCT03523585
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trastuzumab Deruxtecan
show 1 more result
show 1 more result
show 2 more results
show 4 more results
Available safety results
Trastuzumab Deruxtecan
| Dropout rate | 76.8% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results62.5%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 70%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 88.9%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 33.3%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 71.4%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 18.2% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results—Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 25.5% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results0%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 10%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 55.6%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 16.7%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 57.1%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 72.3% alopecia 37.1% vomiting 37.1% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more resultsfatigue 75% constipation 62.5% nausea 50% NCT04420598 · Phase 2 · registry result, not featured evidence fatigue 90% nausea 70% aspartate aminotransferase increased 50% NCT04420598 · Phase 2 · registry result, not featured evidence anaemia 44.4% fatigue 44.4% neutropenia 44.4% NCT04420598 · Phase 2 · registry result, not featured evidence nausea 57.1% anaemia 42.9% fatigue 42.9% NCT04420598 · Phase 2 · registry result, not featured evidence |
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04400695 · Phase 3 · recruiting
This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.
Next expected readout: December 2026 · NCT05831878 (registry estimate)
Reported efficacy
RP2D (Estimated 2 year): Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months (not_applicable)
Result source: NCT03052634
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04494425 · Phase 3 · active, not recruiting
The trial was large and randomized, with an active chemotherapy comparator and a hard clinical primary endpoint of progression-free survival, which was met: median PFS was 13.2 versus 8.1 months, with HR 0.62 and p<0.0001. However, treatment assignment was not blinded, so despite the strong randomized result this is considered moderate evidence rather than strong evidence.
Next expected readout: November 2026 · NCT06048718 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) (met)
Result source: NCT04494425
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Disitamab Vedotin | Trastuzumab Deruxtecan |
|---|---|---|
| PFS, median | —Trial running · NCT05904964 | —Trial running · NCT04494425 |
| OS, median | —Trial running · NCT05904964 | —Trial running · NCT04494425 |
| ORR | —Trial running · NCT05904964 | —Trial running · NCT04494425 |
| Clinical benefit rate | —Trial running · NCT05904964 | —Trial running · NCT04494425 |
PFS, median
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
OS, median
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
ORR
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
Clinical benefit rate
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab Deruxtecan
- —Trial running · NCT04494425
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Trastuzumab Deruxtecan's landscape